Beyond Initial Treatment: Navigating Recurrence Risk and Clinical Decisions in Cancer Survivors
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Emerging artificial intelligence solutions offer promising strategies to address critical
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Emerging artificial intelligence solutions offer promising strategies to address critical
By Léon Van Wouwe, Clinical Innovation Director, Volv Global New data from Roche’s Itovebi (inavolisib) combined with Pfizer’s Ibrance
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction Progressive Pulmonary Fibrosis (PPF) is a severe clinical condition
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Gastric (stomach) cancer remains a formidable global health challenge, ranking
By Christopher Rudolf, Volv Global An AI methodology for finding patients with rare diseases: Volv Global’s inTrigue The Case
